Kantify

At Kantify, we’ve built Sapian - a novel, orthogonal, best-in-class AI platform designed to address key bottlenecks in small-molecule drug discovery. From uncovering new targets to revealing hidden mechanisms of existing compounds, Sapian delivers clear, uniquely accurate, and explainable predictions. Our mission is simple: leverage Sapian’s unique capabilities to expand therapeutic options for diseases with unmet needs. Backed by Innoviris and the European Commission - and collaborating with Johns Hopkins, INSERM, CNRS, Leiden University, IBMCP and partners across Europe, the US and Asia - we’re advancing programs that blend unmatched computational power with experimental validation. If you’re developing small-molecule programs and want a discreet, data-driven edge, let’s talk. Message us here or, preferably, via our website contact form.